2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

PURPOSE: In the last decade, the research community has focused on defining reliable biomarkers for the early detection of Alzheimer’s disease (AD) pathology. In 2017, the Geneva AD Biomarker Roadmap Initiative adapted a framework for the systematic validation of oncological biomarkers to cerebrospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Leuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V., Hansson, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175301/
https://www.ncbi.nlm.nih.gov/pubmed/33674895
http://dx.doi.org/10.1007/s00259-021-05258-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175301/
https://www.ncbi.nlm.nih.gov/pubmed/33674895
http://dx.doi.org/10.1007/s00259-021-05258-7

Ejemplares similares